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Abstract
Purpose. In a previous series of 25 human osteosarcoma samples studied for MYC gene amplification, we found
amplification in two cases (8%), including one arising in association with Paget’s disease (pagetic osteosarcoma). Based
on this observation, we further investigated the prevalence .ofMYC gene amplification in pagetic osteosarcomas.
Methods. MYC gene amplification was assessed by Southern blot analysis using frozen tissue samples in five cases of
pagetic osteosarcoma and 53 cases of primary (non-pagetic) osteosarcoma. Amplification was considered present if the
MYC copy number was six or greater.
Results. Three out of five patients (60%) with pagetic osteosarcoma showed MYC gene amplification, whereas it was
present in only 5/53 patients (9.4%) with primary osteosarcoma. The incidence of MYC amplification in pagetic
osteosarcoma was thus significantly higher than that in primary osteosarcoma (p 0.016).
Discussion. The finding that MYC gene amplification may be more common in pagetic than primary osteosarcoma
warrants further study and suggests pathogenetic differences between primary osteosarcomas and those arising in the
setting of Paget’s disease. Three of the four pagetic osteosarcomas from the present study were previously shown to be
immunoreactive for p53, suggesting that p53 mutation may also be a frequent genetic lesion in these tumors.
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Introduction
Paget’s disease is a benign but precancerous con-
dition affecting the mesenchymal cells of bones. Of
the secondary sarcomas arising in Paget’s disease of
bone, osteosarcomas (pagetic osteosarcomas) are by
far the most common and make up a substantial
proportion of osteosarcomas of late adulthood.
They represent an infrequent but highly lethal com-
plication of Paget’s disease of bone. In a recent
review of the Memorial Sloan-Kettering Cancer
Center (MSKCC) experience with 67 cases of
pagetic sarcoma, we found that sarcoma may be the
initial manifestation of Paget’s disease in up to 50%
of patients with this complication. However,
remarkably little work has been performed on the
molecular genetic basis of sarcomas secondary to
Paget’s disease.
We have recently examined the status of the MYC
gene in a large series of osteosarcomas and found
that only 2/25 patients showed MYC gene
amplification.
3 Of these two patients, one was a
60-year-old man with Paget’s disease and a tibial
osteosarcoma. Based on this observation, we have
further investigated the incidence of MYC gene
amplification in pagetic osteosarcoma and compared
it with that in sporadic osteosarcoma.
Patients and methods
Five samples from five patients with pagetic
osteosarcoma were identified in our osteosarcoma
frozen tissue bank. We also examined 58 frozen
tissue samples from 53 patients with primary (non-
pagetic) osteosarcoma as a control group. All these
cases were confirmed as osteosarcoma by histologi-
cal review (AGH). The results of 25 patients (24
non-pagetic, one pagetic osteosarcoma) included in
the current series have been reported previously.
3
All five samples of pagetic osteosarcoma were
obtained from primary tumors in patients with pre-
viously diagnosed Paget’s disease of bone, while the
sporadic (non-pagetic) osteosarcoma samples were
obtained from 41 primary and 17 metastatic tumors.
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There were three male and two female patients
with an age range of 60-81 years (mean 71.2 years)
among the pagetic osteosarcomas, and 33 male and
20 female patients with an age range of 5-83 years
(mean 25.4 years) in non-pagetic osteosarcomas.
The primary sites of the tumors included the tibia
(two cases), femur (one), humerus (one) and ilium
(one) in the pagetic osteosarcomas, and the femur
(18), tibia (13), humerus (four), ilium (four) and
other sites (14) in the non-pagetic osteosarcomas.
MYC gene amplification was assessed essentially
as previously described.
3 In brief, we performed
quantitative comparison of the Southern blot
hybridization signal of a genomic MYC exon-1
probe (Xho I-Xba I fragment) to that of a probe for
a reference gene on chromosome 8, neurofilament
light polypeptide (NEFL, band 8p21). Signals were
quantified directly on a BioRad Phosphorimager
(Hercules, CA, USA). A reference probe from the
same chromosome was used to control for the non-
specific effect of polyploidization on the quantitation
of gene copy number.
4 HL-60 cell line DNA and
human placental tissue DNA were used as positive
and negative controls for MYC gene amplification,
respectively. The MYC gene is amplified approxi-
mately 16-fold in the HL-60 cell line. To score a
sample as positive, we used a cut-off point of six
copies per cell for the MYC gene amplification
normalized to the signal in human placenta. Frac-
tional amplification values were rounded off to the
nearest whole number.
Results
MYC gene amplification was detected in 3/5
patients (60%) with pagetic osteosarcoma (Fig. 1).
A quantitative analysis of pagetic osteosarcoma
cases 1, 2 and 3 showed amplification levels of 8, 11
and 6 copies per cell, respectively. The other two
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Fig. 1. MYC gene amplification analysis by Southern blotting.
Quantitative comparison of the hybridization signalfor MYC
and the reference probe NF (neurofilament) showed 11 and 6
copies per cell oftheMYC gene in pagetic osteosarcoma cases 2,
and 3, respectively. Amplification is visually apparent in case 2,
but required quantitative confirmation in case 3. Quantitative
analysis in case 5 showedfive copies ofMYC and it was scored
as negativefor amplification. Pagetic osteosarcoma cases 4 and
5 showed no amplification. HL-60 and human placenta,
respectively, were used as positive and negative controls for
amplification.
pagetic osteosarcoma cases, 4 and 5, showed no
amplification. In contrast, only 5/53 patients (9.4%)
with sporadic (non-pagetic) osteosarcoma revealed
MYC gene amplification, ranging from 6 to 15
copies (mean 10 copies). The incidence of
amplification in pagetic osteosarcoma was
significantly higher than that in primary (non-
pagetic) osteosarcoma (60% vs 9.4%, p=0.016
odds ratio: 14.4) by two-tailed Fisher’s exact test
(Table 1).
In previous studies, including some of these cases,
we found that 3/4 pagetic osteosarcomas showed
p53 over-expression, but none showed amplification
ofMDM2 (Table 1).6
Clinical features such as sex and primary site were
Table 1. Data on sporadic osteosarcomas withMYC amplification and osteosarcomas arising in Paget’s disease
Case Sample
number Age/sex Primary. site Histology type p53 IHC MYC*
1. Sporadic:
OS6 7/F Femur Osteoblastic P 7.0
OS 15 37/M Femur Fibrohistiocytic P 3.0
OS39 17/F Tibia Osteoblastic P + 7.5
OS87 33/F Ulna Osteoblastic P ND 3.0
OS 108 8/M Tibia Chondroblastic P ND 4.5
2. Pagetic:
case 1"* 60/M Tibia Osteoblastic P 4.0
case 2 72/M Femur Giant-cell rich P + 5.5
case 3 76/M Humerus Fibrohistiocytic LR + 3.0
case 4 81/F Tibia Fibrohistiocytic P ND 1.0
case 5 67/F Ilium Osteoblastic P + 1.0
*Fold amplification.
**Tumor OS22 in ref. 3.
P: primary; LR: local recurrence; p53 IHC: immunohistochemistry for p53 accumulation using
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not significantly different between pagetic and non-
pagetic osteosarcoma patients, but, as expected, the
former were older (71.2 years in pagetic vs 25.4
years in non-pagetic osteosarcoma). Among the
sporadic osteosarcoma patients, there was also no
significant difference in age distribution between
cases with and without MYC gene amplification.
Case 4 also had a history of Paget’s disease of the
nipple due to extensive underlying intraductal carci-
noma, representing a rare coincidence of these two
eponymous conditions.
Discussion
The MYC proto-oncogene, which maps to chromo-
some band 8q24, encodes a transcription factor
containing dimerization motifs (helix-loop-helix
(HLH) and leucine zipper (LZ)).
7 Normally, MYC
dimerizes with another HLH/LZ protein, MAX,
and interacts with promoters containing the
sequence CACGTG. The spectrum of genes whose
transcription is physiologically regulated by MYC is
a subject of active study. At the cellular level, .MYC
is known to drive cell proliferation in response to
extracellular signals and to promote apoptosis in
proliferating cells upon withdrawal of the same sig-
nals.7 Recently, the cell cycle phosphatase CDC25
has been identified as a direct target of transcrip-
tional activation by MYC, providing the first clear
link between MYC deregulation and cell cycle acti-
vation.
8
The present study of frozen tumor samples of
pagetic and non-pagetic osteosarcomas suggests that
MYC gene amplification is a common molecular
genetic alteration in pagetic osteosarcoma compared
to its low incidence in sporadic osteosarcoma. To
our knowledge, this is the first study of molecular
genetic alterations in pagetic osteosarcomas.
That the MYC proto-oncogene (formerly c-myc)
plays an important role in osteosarcoma has been
noted in various animal models and osteosarcoma
9 cell lines, usually in the form of amplification.
2 In
the murine SEWA osteosarcoma cell line, tumori-
genicity is proportional to the degree ofMYC gene
amplification.
13 However, few samples of human
osteosarcoma have been studied for MYC gene
amplification. Masuda et al.
14 found MYC ampli-
fication in 1/3 osteosarcomas, and Ikeda et al.
15 in
two of four high-grade pediatric osteosarcomas. In
an earlier series, we found MYC gene amplification
in only 2/25 osteosarcomas (8%), one of which was
a pagetic osteosarcoma.
3 More recently, another
group found MYC amplification in 1/8 osteosarco-
mas (13%) of unspecified type.
16 In this study, we
found MYC amplification in 9.4% of sporadic
osteosarcomas. These data suggest that the true
prevalence of MYC gene amplification in sporadic
osteosarcoma is lower than expected from limited
earlier studies. This discrepancy may be due to the
method of quantification and to the use of surgical
specimens, where amplification may be harder to
detect because of admixed non-tumor tissue. Never-
theless, in the present series, pagetic osteosarcomas
revealed a higher prevalence of MYC gene
amplification (60%), suggesting a more important
role forMYC gene amplification in pagetic osteosar-
comas than in primary (non-pagetic) osteosarcomas.
In addition to the potential biological significance
ofMYC gene amplification, its presence may also be
relevant clinically. In some tumor types, the pres-
ence of amplification of specific genes predicts a
poorer prognosis. 17’18 Evidence is now accumulating
that, likewise, MYC gene amplification is associated
with poorer prognosis in musculoskeletal sarcomas
including osteosarcomas. 16’19 Correspondingly, in
some human osteosarcoma cell lines, MYC gene
amplification is associated with higher growth
rate.2’1 Finally, in two cases of pagetic osteosar-
coma, we found a coincidence of MYC
amplification and p53 over-expression (indicative of
p53 point mutation), in contrast to a previous study
22 of these two alterations in sarcomas.
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